<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2214701/" ref="ordinalpos=4120&amp;ncbi_uid=1149450&amp;link_uid=PMC2214701" image-link="/pmc/articles/PMC2214701/figure/F3/" class="imagepopup">Figure 3. A partial view of the canonical Wnt <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>..  From: Building bone to reverse osteoporosis and repair fractures. </a></div><br /><div class="p4l_captionBody">Wnts bind a receptor complex consisting of LRP5 or LRP6 and one of ten Fz proteins. This prevents phosphorylation of β-catenin by GSK3β and other kinases and its subsequent degradation. Of note, mutating the residues that can be phosphorylated to alanine creates stable, gain-of-function β-catenin proteins. Stabilized β-catenin accumulates and translocates to the nucleus, where it interacts with Tcf7 and related transcription factors (Lef1, Tcf7L1, Tcf7L2) to regulate gene expression. Outside the cell, molecules that sequester either LRP5 (e.g., Dkk1 and sclerostin) or the Wnt ligand (e.g., Sfrp) negatively control the canonical Wnt signaling pathway. Lithium chloride inhibits GSK3β inside the cell. APC, adenomatosis polyposis coli.</div></div>